Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum, characterised by bloody diarrhoea, urgency, abdominal pain, and systemic complications including anaemia and extraintestinal manifestations.
Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum, characterised by bloody diarrhoea, urgency, abdominal pain, and systemic complications including anaemia and extraintestinal manifestations. Modern management combines 5-aminosalicylate agents, immunosuppression, and biologic therapies; however, a significant proportion of patients experience relapsing disease or intolerance to standard drugs. Mesenchymal stem cell research in UC explores whether cell-derived immunomodulatory factors might suppress mucosal inflammation and promote tissue healing. Related approved therapies (such as an MSC product indicated for perianal Crohn's fistulae) provide mechanistic precedent, though this distinct indication remains investigational in UC.
| Cost indicativ · Bulgaria (UE) | €3,000–€8,000 |
|---|---|
| Gama costurilor pieței globale | €20,000–€27,500 (dvcstem.com) |
| Principalele tipuri de celule studiate | MSC de la membrana amniotică |
| Statutul aprobării | Investigațional |
| Studii înregistrate (ClinicalTrials.gov) | 14 |
For the clinic's own description, see our partner clinic Stem Plus.
Fourteen registered trials are examining stem cell or MSC-derived approaches in ulcerative colitis populations worldwide. A 2022 phase II study involving 41 UC patients receiving intravenous allogeneic placental MSCs showed clinical remission rates of 61% at week 12, versus 24% in the placebo arm. Endoscopic inflammation scores improved significantly in the treatment group. However, this trial lacked a blinded design, and a subsequent meta-analysis of 9 UC stem cell trials (total n=187) reported heterogeneous outcomes with clinical remission ranging 35–68%. No phase III trial data have been published. Mechanistic studies indicate tumour necrosis factor suppression and regulatory T-cell expansion.
Depending on assessment, a Ulcerative Colitis protocol may draw on:
UC-targeted stem cell infusions are offered in South Korea, Turkey, and select European centres at costs ranging from €3,500–€8,000 per course. UK private clinics are sparse; overseas treatment requires travel. Standard UC pharmacotherapy (biologic agents like infliximab or vedolizumab) costs £3,000–£10,000 annually through private UK insurers, though NHS provides these at no out-of-pocket cost for eligible patients. Stem cell therapy's cost-benefit remains unfavourable in healthcare systems where biologics are accessible, though individual circumstances vary. Out-of-pocket stem cell expenditure may exceed annual pharmaceutical costs within a single treatment cycle.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Ulcerative Colitis cost-by-country breakdown, or compare the best countries for Ulcerative Colitis →
Before booking, check safety & regulation, the recovery climate, dacă ai putea fi candidat, and which cell type fits Ulcerative Colitis.
FAQ complet Colită Ulcerativă → · Defalcare costuri Colită Ulcerativă →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Sunt eu un candidat? · Ce tip de celulă? · Types of clinics & best countries · Calculator de costuri
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită